Literature DB >> 15215619

Effects of recombinant cholera toxin b subunit (rCTB) on cellular immune responses: enhancement of delayed-type hypersensitivity following intranasal co-administration of Mycobacterium bovis-BCG with rCTB.

Jun-Ichi Maeyama1, Masanori Isaka, Yoko Yasuda, Keiko Matano, Kazunori Morokuma, Kunio Ohkuma, Kunio Tochikubo, Saburo Yamamoto, Norihisa Goto.   

Abstract

Recombinant cholera toxin B subunit (rCTB) is a safe and potent mucosal adjuvant. To gain insight into the mechanism underlying the adjuvant effect of rCTB, the effects of rCTB on cell-mediated immune responses of mice and guinea pigs were examined after intranasal administration of Mycobacterium bovis -bacillus Calmette-Guérin (BCG) with and without rCTB. Delayed-type hypersensitivity, for skin reactions in guinea pigs and for footpad swelling reactions in mice, to purified protein derivative (PPD) were enhanced by intranasal co-administration of BCG and rCTB, as compared to giving BCG alone to these animals. Moreover, tumor necrosis factor (TNF)-alpha and interferon (IFN)-gamma production of spleen cells and antigen specific spleen cell proliferation, stimulated with PPD, were enhanced in the presence of rCTB. These results strongly suggest that rCTB enhances cellular as well as humoral immune responses.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15215619     DOI: 10.1111/j.1348-0421.2004.tb03536.x

Source DB:  PubMed          Journal:  Microbiol Immunol        ISSN: 0385-5600            Impact factor:   1.955


  3 in total

1.  Cholera toxin induces a shift from inactive to active cyclooxygenase 2 in alveolar macrophages activated by Mycobacterium bovis BCG.

Authors:  Mari Kogiso; Tsutomu Shinohara; C Kathleen Dorey; Yoshimi Shibata
Journal:  Infect Immun       Date:  2012-11-12       Impact factor: 3.441

2.  Differential requirements for protection against mucosal challenge with Francisella tularensis in the presence versus absence of cholera toxin B and inactivated F. tularensis.

Authors:  Constantine Bitsaktsis; Deepak B Rawool; Ying Li; Nitin V Kurkure; Bibiana Iglesias; Edmund J Gosselin
Journal:  J Immunol       Date:  2009-04-15       Impact factor: 5.422

3.  Development of safe, effective and immunogenic vaccine candidate for diarrheagenic Escherichia coli main pathotypes in a mouse model.

Authors:  Asmaa Gohar; Nourtan F Abdeltawab; Ali Fahmy; Magdy A Amin
Journal:  BMC Res Notes       Date:  2016-02-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.